Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

D-Penicillamine administration and the incidence of retinopathy of prematurity

Abstract

Objective:

We compared the development of retinopathy of prematurity (ROP) among 49 preterm neonates:; 15 who were treated during the first 2 weeks of life with D-penicillamine and 34 who were not.

Methods:

During a 15-month period beginning 1 March, 2005, 15 preterm neonates <1000 g birth weight or 29 weeks gestation enterally received a 14-day course of D-penicillamine, and 34 did not, in an open-label non-randomized trial. We compared the outcomes of developing ‘ROP any stage’ and ‘ROP requiring surgery’ in the recipients vs the non-recipients. Potential toxicities of the D-penicillamine were examined by comparing specific laboratory tests, growth velocities, transfusion requirements, discharge hemoglobin concentrations and supplemental O2 at discharge.

Results:

The 34 non-treated and the 15 D-penicillamine treated patients were of similar gestational age (26.5±1.8 vs 26.6±2.2 weeks, mean±s.d.) and birth weight (887±222 vs 849±187 g). Four of the 34 non-recipients died. Eighteen of the 30 survivors (60%) developed ROP and seven of the 30 (23%) had ROP surgery. One of the 15 D-penicillamine recipients died. Three of the 14 survivors (21%) developed ROP (P=0.01 vs non-recipients) and all three had ROP laser surgery. No increase in elevated creatinine, direct or indirect bilirubin, thrombocytopenia or neutropenia was apparent in those treated with D-penicillamine. The D-penicillamine recipients did not receive more transfusions and did not have lower hemoglobin concentrations at discharge. They did not have lower velocities of weight gain at 14, 28 and 56 days, and were not discharged on supplemental O2 at a rate exceeding that of the non-recipients.

Conclusions:

In this non-randomized, single-centered comparison analysis, a 14-day course of D-penicillamine resulted in no apparent short-term toxicity. The treatment was associated with elimination of Stage I and Stage II ROP, decreasing the overall odds of developing ROP from 60 to 21%. However, this approach did not reduce the odds of ROP surgery. Perhaps higher doses of D-penicillamine or longer treatment periods or other prophylactic approaches will be required to reduce ROP surgery among the most immature neonates.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Christensen RD, Alder SC, Richards SC, Horn JT, Lambert DK, Baer VL . A pilot trial testing the feasibility of administering D-penicillamine to extremely low birth weight neonates. J Perinatol 2006; 26: 120–124.

    Article  CAS  Google Scholar 

  2. Phelps DL, ETROP Cooperative Group. The early treatment for retinopathy of prematurity study: better outcomes, changing strategy. Pediatrics 2004; 114: 490–491.

    Article  Google Scholar 

  3. Haines L, Fielder AR, Baker H, Wilkinson AR . UK population based study of severe retinopathy of prematurity: screening, treatment, and outcome. Arch Dis Child Fetal Neonatal Ed 2005; 90: F240–F244.

    Article  CAS  Google Scholar 

  4. http://www.nei.nih.gov/health/rop/index.asp.

  5. Aiello LP . Vascular endothelial growth factor and the eye – past, present, and future. Arch Ophthalmol 1996; 114: 1252–1254.

    Article  CAS  Google Scholar 

  6. Aiello LP . Vascular endothelial growth factor. 20th-century mechanisms, 21st-century therapies. Invest Ophthalmol Vis Sci 1997; 38: 1647–1652.

    CAS  PubMed  Google Scholar 

  7. Polytarchou C, Papadimitriou E . Antioxidants inhibit angiogenesis in vivo through down-regulation of nitric oxide synthase expression and activity. Free Radic Res 2004; 38: 501–508.

    Article  CAS  Google Scholar 

  8. Stone JS, Collins T . The role of hydrogen peroxide in endothelial proliferative responses. Endothelium 2002; 9: 231–238.

    Article  CAS  Google Scholar 

  9. Ushio-Fukai M, Alexander RW . Reactive oxygen species as mediators of angiogenesis signaling: role of NAD(P)H oxide. Mol Cell Biochem 2004; 264: 85–97.

    Article  CAS  Google Scholar 

  10. Hunt JT, Lee VG, Liu ECK et al. Control of peptide disulfide regioisomer formation by mixed cysteine-penicillamine bridges. Int J Peptide Protein Res 1993; 42: 249–258.

    Article  CAS  Google Scholar 

  11. Matsubara T, Saura R, Hirohata K . Inhibition of human endothelial cell proliferation in vitro and neovasularization in vivo by D-penicillamine. J Clin Invest 1989; 83: 158–167.

    Article  CAS  Google Scholar 

  12. Yoshida D, Ikeda Y, Nakazawa S . Copper chelation inhibits tumor angiogenesis in the experimental 9L gliosarcoma model. Neurosurgery 1995; 37: 287–292.

    Article  CAS  Google Scholar 

  13. Pietraforte D, Mallozzi C, Scorza G, Minetti M . Role of thiols in the targeting of S-nitroso thiols to red blood cells. Biochemistry 1995; 34: 7177–7185.

    Article  CAS  Google Scholar 

  14. McBrien NA, Norton TT . Prevention of collagen crosslinking increases form-deprivation myopia in tree shrew. Exp Eye Res 1994; 59: 475–486.

    Article  CAS  Google Scholar 

  15. Siemeister G, Schnurr B, Mohrs K, Schachtele C, Marme D, Martiny-Baron G . Expression of biologically active isoforms of the tumor angiogenesis factor VEGF in Escherichia coli. Biochem Biophys Res Commun 1996; 222: 249–255.

    Article  CAS  Google Scholar 

  16. Lakatos L, Kover B, Oroszlan GY, Vekerdy ZS . -Penicillamine therapy in ABO hemolytic disease of the newborn infant. Eur J Pediatr 1976; 123: 133–137.

    Article  CAS  Google Scholar 

  17. Lakatos L, Hatvani I, Oroszlan G, Balla G, Karmazsin L, Alaka O et al. Controlled trial of D-penicillamine to prevent retinopathy of prematurity. Acta Paediatr Hungar 1986; 27: 47–56.

    CAS  Google Scholar 

  18. Phelps DL, Lakatos L, Watts JL . -Penicillamine for preventing retinopathy of prematurity in preterm infants. Cochrane Database Syst Rev 2001; (1): CD001073.

  19. Lambert DK, Ercal N, Richards SC, Veng-Peterson P, Horn JT, Richards M et al. Pharmacokinetics of D-penicillamine after enteral administration to preterm neonates. Submitted for publication 2006.

  20. An International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity Revisited. Arch Ophthalmol 2005; 123: 991–995.

  21. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. One-year outcome – structure and function. Arch Ophthalmol 1990; 108: 1408–1416.

  22. Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity – results of the ETROP randomized trial. Arch Ophthalmol 2003; 121: 1684–1696.

  23. Gilbert C, Fielder A, Gordillo L, Guinn G, Semiglia R, Visintin P et al. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implication for screening programs. Pediatrics 2005; 115: e518–e525.

    Article  Google Scholar 

  24. Phelps DL, Watts JL . Early light reduction to prevent retinopathy of prematurity in very low birth weight infants In: Cochrane Database Syst Rev. 2001; (1) CD 000122.

  25. STOP-ROP Multicenter Trial. Supplemental therapeutic oxygen for prethrehold retinopathy of prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. Pediatrics 2000; 105: 295–310.

  26. Saugstad OD . Oxygen for newborns: how much is too much? J Perinatol 2005; 25 (Suppl 2): S45–S49.

    Article  Google Scholar 

  27. Friedman CA, McVey J, Borne MJ, James M, May WL, Temple DM et al. Relationship between serum inositol concentration and development of retinopathy of prematurity: a prospective study. J Pediatr Ophthalmol Strabismus 2000; 37: 79–86.

    CAS  PubMed  Google Scholar 

  28. Howlett A, Ohlsson A . Inositol for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev 2003; (4): CD000366.

  29. Flynn JT, Chan-Ling T . Retinopathy of prematurity: two distinct mechanisms that underlie zone 1 and zone 2 disease. Am J Ophthalmol 2006; 142: 46–59.

    Article  Google Scholar 

  30. Werdich XQ, McCollum GW, Rajaratnam VS, Penn JS . Variable oxygen and retinal VEGF levels: correlation with incidence and severity of pathology in a rat model of oxygen-induced retinopathy. Exp Eye Res 2004; 79: 623–630.

    Article  CAS  Google Scholar 

  31. May CA, Ohlmann AV, Hammes H, Spandau UH . Proteins with an endostatin-like domain in a mouse model of oxygen-induced retinopathy. Exp Eye Res 2006; 82: 341–348.

    Article  CAS  Google Scholar 

  32. Jensen L, Schjerling P, Hellsten Y . Regulation of VEGF and bFGF mRNA expression and other proliferative compounds in skeletal muscle cells. Angiogenesis 2004; 7: 255–267.

    Article  CAS  Google Scholar 

  33. Voelkel NF, Vandivier RW, Tuder RM . Vascular endothelial growth factor in the lung. Am J Physiol Lung Cell Mol Physiol 2006; 290: L209–221.

    Article  CAS  Google Scholar 

  34. Drosos AA, Geogriou P, Politi EN, Voulgori PV . -penicillamine in early rheumatoid arthritis. Clin Exp Rheumatol 1997; 15: 580–581.

    CAS  PubMed  Google Scholar 

  35. Vekerdy-Lakatos S, Lakatos L, Oroszlan G, Itzes B . One year longitudinal follow-up of premature infants treated with D-penicillamine in the neonatal period. Acta Paediatr Hung 1987; 28: 9–16.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Dr L Lakatos, Professor of Pediatrics, Kenezy County Hospital, Debrecen, Hungary for helpful discussions. We also thank Faith A Smith, RN, BSN, for her encouragement and the NICU nurses of the McKay-Dee Hospital Center for their valuable assistance with the study. This study was supported in part by a grant from the Thrasher Research Fund.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to R D Christensen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Christensen, R., Alder, S., Richards, S. et al. D-Penicillamine administration and the incidence of retinopathy of prematurity. J Perinatol 27, 103–111 (2007). https://doi.org/10.1038/sj.jp.7211653

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jp.7211653

Keywords

This article is cited by

Search

Quick links